FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research report released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on FGEN. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of FibroGen in a research report on Thursday, February 20th.

FibroGen Trading Down 5.0 %

Shares of NASDAQ:FGEN opened at $0.37 on Thursday. The stock has a market capitalization of $37.37 million, a PE ratio of -0.30 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The firm has a fifty day moving average price of $0.52 and a 200 day moving average price of $0.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FGEN. JPMorgan Chase & Co. lifted its position in FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 605,572 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of FibroGen by 416.6% during the fourth quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 441,083 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of FibroGen during the fourth quarter valued at about $205,000. Finally, Two Sigma Advisers LP raised its position in shares of FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 135,600 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.